Abraxis Biosciences, a Los Angeles-based biotechnology company, unveiled a $70-million biopharmaceutical manufacturing plant in Phoenix, to serve as the company's manufacturing site for its pipeline of biologics.
Abraxis Biosciences, a Los Angeles-based biotechnology company, unveiled a $70-million biopharmaceutical manufacturing plant in Phoenix, to serve as the company's manufacturing site for its pipeline of biologics.
Initially, the new facility will be used to make Abraxane, the company's chemotherapy drug to treat metastatic breast cancer. The site will have an annual production capacity of over 10 million units, and the capability to expand to 20 million units, suitable for worldwide distribution.
According to the Founder and Chairman Patrick Soon-Shiong, the new plant will create up to 200 technology jobs.Abraxis plans to launch commercial production at the Phoenix facility in late 2010.
